Pharma BD Deal Intelligence
A small sterile-injectables bolt-on that took a near-50%-of-deal-value impairment within two years and then vanished into the much larger Hospira acquisition — a quiet underperformer, not a scandal.
Full analysis, sources & comparables →Pfizer said today it will acquire InnoPharma for $225 million upfront, plus an additional up-to-$135 million tied to milestones.
Pfizer increased its position in the $7 billion-plus market for sterile injectable drugs with a $360 million agreement to buy New Jersey-based InnoPharma;…
Pfizer Injectables can capitalize on synergies by applying its existing manufacturing, production and sales muscle to InnoPharma's robust complex injectables…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pfizer agreed to acquire privately held NJ-based InnoPharma for $225M upfront plus up to $135M in milestones, building out a sterile injectables and specialty-injectable pipeline ahead of its 2015 Hospira mega-deal. Closed September 25, 2014.
A small sterile-injectables bolt-on that took a near-50%-of-deal-value impairment within two years and then vanished into the much larger Hospira acquisition — a quiet underperformer, not a scandal.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / InnoPharma, Inc. (this deal) | 2014 | $360M | 36 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Pfizer Inc. deals · Neurology deals